^
    Back
    Association details:
    Biomarker:PD-L1 expression + TMB-H
    Cancer:Skin Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    BMJ Case Rep
    Title:

    Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa

    Published date:
    02/26/2021
    Excerpt:
    A 30-year-old woman with RDEB and multiple unresectable cSCCs was found to have high tumour mutational burden and PD-L1 (programmed cell death-ligand 1) expression. She was started on an ICI, which yielded disease control and was well tolerated.
    DOI:
    10.1136/bcr-2020-238966